Page

MAIL STOP PCT Serial Number: 10/518,413 Attorney Docket: 26465U Filing Date: December 17, 2004 FORM PTO-1449 International Application Number: Inventor: PCT/EP03/06435 LOOS International Filing Date: Group Art Unit: INFORMATION DISCLOSURE CITATION 18 June 2004 Unknown U.S. PATENT DOCUMENTS Class Filing Date Class Document Number Initial A1 FOREIGN PATENT DOCUMENTS Translation Class Class Document Number Date OTHER (Including Author, Title, Date, Pertinent Pages, etc.) "Iodide transport in the thyroid gland", Biochimica et Biophysica Acta, Carrasco, N., "Iodide transpo Vol. 1154, Pp. 65-82, (1993). **A3** De La Vieja, A., et al., "Molecular Analysis of the Sodium/Iodide Symporter: Impact on Thyroid and Extrathyroid Pathophysiology", Physiological Reviews, Vol. 80, No. 3, Pp. A4 1083-1105, (2000). Heufelder, A.E., "Sodium Iodide Symporter-Based Strategies for Diagnosis and Treatment of Thyroidal and Nonthyroidal Malignancies", THYROID, Vol. 11, No. 9, Pp. 839-847, (2001). **A5** Inoue, K., "Expression of Peroxisome Proliferator-Activated Receptor (PPAR)- ↑ in Human Lung Cancer", Anticancer Research, Vol. 21, Pp. 2471-2476, (2001). Α6 Kilgore, M.W., "MCF-7 and T47D human breast cancer cells contain a functional peroxisomal response", Molecular and Cellular Endocrinology, Vol. 129, Pp. 229-235, (1997). Α7 Kogai, T., "Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line" PHAS, Vol. 97, No. 15, Pp. 8519-8524, **A8** Braverman, L.E., et al., (Ed.), "Chapter 80: Carcinoma of Follicular Epithelium", Werner and Ingbar's: The Thyroid, 7th Ed., Lippincott-Raven Publishers: New York, Pp. 922-944, A9 Murphy, G.J., et al., "PPAR- 🌱 agonists: therapeutic role in diabetes, inflammation and cancer", TiPS, Vol. 21, Pp. 469-474, (2000). Nwankwo, J.O., et al., "Peroxisome proliferator-activated receptor- γ expression in human malignant and normal brain, breast and prostate-derived cells, <u>Prostaglandins</u>, <u>Leukotrienes and Essential Fatty Acids</u>, Vol. 64, No. 4 and 5, Pp. 241-245, (2001). A11 Riedel, C., et al., "Journey of the iodide transporter NIS: from its molecular identification to its clinical role in cancer", TRENDS in Biochemical Sciences, Vol. 26, A12 No. 8, Pp. 490-496, (2001). Sugiyama, Y., et al., "Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects", Nippon Rinsho, Vol. 58, No. 2, Pp. 370-375, (2000). A13 Tazebay, U.H., et al., "The mammary gland iodide transporter is expressed during lactation and in breast cancer", Nature Medicine, Vol. 4, No. 8, Pp. 871-878, (2000). A14 Titcomb, M.W., et al., "Sensitive and Specific Detection of Retinoid Receptor Subtype Proteins in Cultured Cell and Tumor Extracts", Molecular Endocrinology, Vol. 8, No. 7, A15 Pp. 870-877, (1994). Ide, T., et al., "Cross-Talk between Peroxisome Proliferator-Activated Receptor (PPAR) **α** and Liver X Receptor (LXR) in Nutritional Regulation of Fatty Acid Metabolism. II. LXRs Suppress Lipid Degradation Gene Promoters through Inhibition of PPAR Signaling", Molecular Endocrinology, Vol. 17, No. 7, Pp. 1255-1267, (2003). A16 Behr, M., et al., "Periodically hyperthyroid phenotype in thyroid hormone resistance is associated with mutation D322N in the thyroid hormone receptor & gene: Transcriptional properties of the mutant and the role of retinoid X receptor", Exp Clin Endocrinol Diabetes, Vol. 104, Suppl. 4, Pp. 111-116, (1996). A17 Schumtzler, C., "Regulation of the sodium/iodide symporter by retinoids - a review", Exp. A18 Clin. Endocrinol. Diabetes, Vol. 109, Pp. 41-44, (2001). Schumtzler, C., et al., "Treatment of Prostate Cancer by Radioiodine Therapy after A19 Tissue-specific Expression of the Sodium Iodide Symporter", Cancer Research, Vol. 60, Pp. 6526-6530, (2000). Spitzweg, C., et al., "In vivo sodium iodide symporter gene therapy of prostate cancer", A20 Gene Therapy, Vol. 8, Pp. 1524-1531, (2001). Date Considered Examiner /Lance Rider/ 02/24/2010

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.